Loading...
Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life.
Richards, M A Hopwood, Penelope Ramirez, A J Twelves, C J Ferguson, Janice E Gregory, W M Swindell, Ric Scrivener, W Miller, J Howell, Anthony
Richards, M A
Hopwood, Penelope
Ramirez, A J
Twelves, C J
Ferguson, Janice E
Gregory, W M
Swindell, Ric
Scrivener, W
Miller, J
Howell, Anthony
Citations
Altmetric:
Abstract
The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.
Description
Date
1992
Publisher
Collections
Keywords
Breast Cancer
Cancer Metastasis
Cancer Recurrence
Cancer Metastasis
Cancer Recurrence
Type
Article
Citation
Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. 1992, 28A (6-7):1023-8 Eur J Cancer